CTI BioPharma (CTIC) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTIC, but not buy additional shares or sell existing shares.
View CTIC analyst ratings or view top-rated stocks.

7 brokerages have issued 1 year target prices for CTI BioPharma's stock. Their CTIC share price forecasts range from $8.00 to $13.00. On average, they expect the company's stock price to reach $9.75 in the next year. This suggests a possible upside of 7.3% from the stock's current price.
View analysts price targets for CTIC or view top-rated stocks among Wall Street analysts.

CTI BioPharma Corp. (NASDAQ:CTIC) issued its quarterly earnings data on Monday, March, 6th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to the consensus estimate of $24.88 million. During the same quarter last year, the firm earned ($0.38) EPS.

CTI BioPharma shares reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

One share of CTIC stock can currently be purchased for approximately $9.09.

CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $1.20 billion and generates $53 million in revenue each year. The biopharmaceutical company earns $-92,990,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

The company employs 127 workers across the globe.

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206.